Home › NCT07602374
Efficacy of Written Versus Video Patient Education Materials for Postmastectomy Breast Reconstruction
Evaluating the Efficacy of Written Versus Video Patient Education Materials for Postmastectomy Breast Reconstruction Patients: Knowledge, Confidence, and Anxiety
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Adults aged 18 or older * Presenting as a new patient to the UCSF plastic surgery breast reconstruction clinic * Considering mastectomy, including: * \- Therapeutic mastectomy in the setting of a breast cancer diagnosis * \- Prophylactic mastectomy in the setting of a confirmed high-risk genetic variant * \- Staged procedures, including delayed mastectomy with initial reduction * Participants who are undecided between lumpectomy and mastectomy Exclusion Criteria: * Established patients returning for follow-up, in order to minimize confounding variables of individual surgeon education style on outcome measures * Participants who are primarily considering lumpectomy or oncoplastic reduction at the time of their visit * Non-English speakers, as educational materials are currently available in English only
About the study
This is a prospective, randomized controlled trial evaluating the comparative efficacy of written, video, and combined written and video patient education materials relative to no supplemental education for University of California, San Francisco (UCSF) patients presenting for post-mastectomy breast reconstruction consultation.
What is being tested
- Questionnaires (other)
- Video Health Education Materials (other)
- Written Health Education Materials (other)
- Medical Chart Review (other)
Sponsor: University of California, San Francisco · Participants: 100 · Started: Jun 6, 2026
Contact the study team
- Reta Behman, BA · Phone: 877-827-3222
Official record on ClinicalTrials.gov — NCT07602374
Locations in the U.S.
| California | University of California, San Francisco, San Francisco |
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.